Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -33981.76% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-33981.76%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Parabilis Medicines, Inc.
Market Cap
$3.33B
EBITDA Margin
-33981.76%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.39B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$3.43B
EBITDA Margin
-21676.57%
TTM Avg
-21676.57%
3Y Avg
-14888.43%
5Y Avg
-11379.97%
Market Cap
$3.19B
EBITDA Margin
-15.32%
TTM Avg
-40.28%
3Y Avg
-284.43%
5Y Avg
-231.70%
Market Cap
$3.48B
EBITDA Margin
-70.74%
TTM Avg
-2343.52%
3Y Avg
-1340.84%
5Y Avg
-951.82%
Market Cap
$3.49B
EBITDA Margin
-4940.36%
TTM Avg
-4940.36%
3Y Avg
-3147.19%
5Y Avg
-1703.30%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.33B | -33981.76% | N/A | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.33B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 10.88% | 18.32% | -3.89% | -19.05% |
| CareDx, Inc (CDNA)vs › | $3.39B | -1.23% | 8.45% | -16.90% | -13.40% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | -21676.57% | -21676.57% | -14888.43% | -11379.97% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | -15.32% | -40.28% | -284.43% | -231.70% |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -70.74% | -2343.52% | -1340.84% | -951.82% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.49B | -4940.36% | -4940.36% | -3147.19% | -1703.30% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.51B | -174.74% | -257.44% | -315.29% | -346.07% |
Gross Margin
0.0%
EBITDA Margin
-33981.8%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -33981.76% |
